Varying recurrence rates and risk factors associated with different definitions of local recurrence in patients with surgically resected, stage I nonsmall cell lung cancer

Cancer

Volumn 116, Issue 10, 2010, Pages 2390-2400

  Varlotto, John M ^a   Recht, Abram ^b   Flickinger, John C ^c   Medford Davis, Laura N ^d   Dyer, Anne Marie ^e   DeCamp, Malcolm M ^b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Disease recurrence; Lung cancer; Stage I; Surgical resection

Indexed keywords

AGED; ARTICLE; BRONCHUS; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; DIABETES MELLITUS; FOLLOW UP; HISTOLOGY; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; TREATMENT FAILURE; TUMOR VOLUME; LUNG TUMOR; PATHOLOGY; RECURRENT DISEASE; TUMOR RECURRENCE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RISK FACTORS;

EID: 77952568270     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25047     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Chang JY, Bradley JD, Govindan R, et al. Perez and Brady's Principle and Practice of Radiation Oncology. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2008.
3. Douillard J, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected state IB-IIIA non-small cell lung cancer(Adjuvant Nalvelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006;7:719-727.
4. Mayer R, Smolle-Juettner F-M, Szolar D, et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest. 1997;112:954-959. (Pubitemid 27446314)
5. Lafitte JJ, Ribet ME, Prevost BM, et al. Postresection irradiation for T2 N0 M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg. 1996;62:830-834. (Pubitemid 26301784)
6. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2000;47: 925-929. (Pubitemid 30345589)
7. Lung Cancer Study Group. Effects of postoperative media-stinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med. 1986;315: 1377-1381.
8. Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer. 1999;86:265-273.
9. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60:615-623.
10. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol. 2002;62:11-19.
11. Debevec M, Bitenc M, Vidmar S, et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study 1988-1992. Lung Cancer. 1996;14:99-107. (Pubitemid 26079516)
12. Stephens RJ, Girling DJ, Bleehen NM, et al. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1996;74:632-639.
13. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys. 1980; 6:983-986. (Pubitemid 10004395)
14. Kelsey CR, Light KL, Marks LB. Patterns of failure after resection of non-small cell lung cancer: implications for postoperative radiation therapy volumes. Int J Radiat Oncol Biol Phys. 2006;65:1097-1105. (Pubitemid 43914213)
15. Orlow I, Park BJ, Mujumdar U, et al. DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. J Clin Oncol. 2008;26:3560-3565.
16. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606-612.
17. Kaplan ES, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
18. Cox DR. Regression models and life table. J R Stat Soc B. 1972;34:187-220.
19. PORT Meta-Analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from 9 randomised controlled trials. Lancet. 1998;352:257-263.
20. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, DeCamp MM. Factors associated with local and distant recurrence and survival in patients with resected non-small cell lung cancer. Cancer. 2009;115:1059-1069.
21. Shields TW. Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet. 1983;157:185-190.
22. Goldstein NS, Mani A, Chmielewski G, et al. Prognostic factors in T1N0M0 adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am J Clin Pathol. 1999;112:391-402. (Pubitemid 30214780)
23. Cagini L, Monacelli M, Giustozzi G, et al. Biological prognostic factors for early stage completely resected non-small lung cancer. J Surg Oncol. 2000;74:53-60.
24. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565-574.
25. Callee EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348: 1625-1638.
26. Park SM, Lim MK, Jung KW, et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol. 2007;25:4835-4843.
27. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293:194-202.
28. Gapstur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000; 283:2552-2558.
29. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007;25:1476-1481.
30. Hazra S, Batra RK, Tai HH, et al. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol. 2007;71:1715-1720. (Pubitemid 47010924)
31. Jiralerspong S, Giordano SH, Meric-Bernstam F, et al. The effects of metformin on pathologic complete response (pCR) rates in diabetic breast cancer (BC) patients receiving neoadjuvant systemic therapy [abstract]. J Clin Oncol. 2008; 26(15 suppl):13S. Abstract 528.
32. Mountain CF. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest. 1995;108: 246-254.
33. Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population- based data. Semin Surg Oncol. 1994;10:21-30.
34. Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer. 1970;25: 362-367.
35. Whelan RL. Laparotomy, laparoscopy, cancer, and beyond. Surg Endosc. 2001;15:110-115.
36. Weighardt H, Heidecke C-D, Emmanuilidis K, et al. Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of the monocyte production. Surgery. 2000;127:309-315. (Pubitemid 30140629)
37. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043-5051.